In the phase III trial OlympiAD, patients with advanced HER2-negative BC and confirmed or suspected deleterious gBRCAm who had received no more than two previous chemotherapy regimens for metastatic disease and at least one endocrine therapy for hormone-receptor-positive disease were assigned to either olaparib monotherapy or standard-of-care chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.